Last reviewed · How we verify
HDAC inhibitor SB939
HDAC inhibitor SB939 is a Histone deacetylase inhibitor Small molecule drug developed by NCIC Clinical Trials Group. It is currently in Phase 2 development for Lymphoma.
Histone deacetylase inhibitor
Histone deacetylase inhibitor Used for Lymphoma.
At a glance
| Generic name | HDAC inhibitor SB939 |
|---|---|
| Sponsor | NCIC Clinical Trials Group |
| Drug class | Histone deacetylase inhibitor |
| Target | Histone deacetylase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
SB939 is a potent inhibitor of histone deacetylase enzymes, which play a crucial role in the regulation of gene expression.
Approved indications
- Lymphoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
Key clinical trials
- A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas (PHASE2)
- A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia (PHASE1)
- SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer (PHASE2)
- SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (PHASE1)
- An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia (PHASE3)
- A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes (PHASE2)
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDAC inhibitor SB939 CI brief — competitive landscape report
- HDAC inhibitor SB939 updates RSS · CI watch RSS
- NCIC Clinical Trials Group portfolio CI
Frequently asked questions about HDAC inhibitor SB939
What is HDAC inhibitor SB939?
HDAC inhibitor SB939 is a Histone deacetylase inhibitor drug developed by NCIC Clinical Trials Group, indicated for Lymphoma.
How does HDAC inhibitor SB939 work?
Histone deacetylase inhibitor
What is HDAC inhibitor SB939 used for?
HDAC inhibitor SB939 is indicated for Lymphoma.
Who makes HDAC inhibitor SB939?
HDAC inhibitor SB939 is developed by NCIC Clinical Trials Group (see full NCIC Clinical Trials Group pipeline at /company/ncic-clinical-trials-group).
What drug class is HDAC inhibitor SB939 in?
HDAC inhibitor SB939 belongs to the Histone deacetylase inhibitor class. See all Histone deacetylase inhibitor drugs at /class/histone-deacetylase-inhibitor.
What development phase is HDAC inhibitor SB939 in?
HDAC inhibitor SB939 is in Phase 2.
What are the side effects of HDAC inhibitor SB939?
Common side effects of HDAC inhibitor SB939 include Fatigue, Diarrhea, Nausea.
What does HDAC inhibitor SB939 target?
HDAC inhibitor SB939 targets Histone deacetylase and is a Histone deacetylase inhibitor.
Related
- Drug class: All Histone deacetylase inhibitor drugs
- Target: All drugs targeting Histone deacetylase
- Manufacturer: NCIC Clinical Trials Group — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Lymphoma
- Compare: HDAC inhibitor SB939 vs similar drugs
- Pricing: HDAC inhibitor SB939 cost, discount & access